Auto-SCT in severe paraproteinemic neuropathy

Hummel, Horst; Rath, Julie; Wiendl, Heinz; Hetzel, W. D.; Bargou, Ralf C.; Toyka, Klaus V.; Sommer, CM; Einsele, H.; Topp, Max S.

doi:10.1038/bmt.2010.124

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Efficacy of SCT for refractory polyneuropathy associated with B cell dyscrasia has not been studied systematically. Case reports have documented improvement after SCT in some patients with CIDP (7 patients), POEMS (42 patients) [ 5 – 8 ] and most recently in four patients with MGUS associated neuropathy [ 10 ], but publication bias may have precluded reports of cases with an unfavorable outcome. SCT results ranged from complete remission of the neuropathy in some POEMS and CIDP patients to full relapse after initial improvement, and unresponsiveness to SCT.…”

Section: Discussionmentioning

confidence: 99%

“…Hematological stem cell therapy (SCT) is a well-established therapy used for refractory hematological malignancies. SCT has been reported to attenuate the progressive disease course of patients with polyneuropathy with organomegaly, endocrinopathy, M-protein and skin changes (POEMS) [ 5 , 6 ], chronic inflammatory demyelinating polyneuropathy (CIDP) [ 7 , 8 ], primary AL amyloidosis [ 9 ], and recently in a small series of patients with IgG MGUS- or MM-associated neuropathy [ 10 ], but it is unknown whether SCT may represent a rescue therapy for a wider range of patients with polyneuropathy and B cell dyscrasias and whether the possible beneficial effects outweigh risks associated with SCT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of stem cell transplantation for B-cell malignancies on disease course of associated polyneuropathy

et al. 2012

View full text Add to dashboard Cite

B cell dyscrasias are often refractory to medical treatments, and hematological stem cell therapy (SCT) may be warranted. It is not clear whether an associated polyneuropathy may also profit from SCT. In exceptional cases SCT has been tried in patients with monoclonal gammopathy and progressive polyneuropathy refractory to medical treatments. In a cohort of 225 patients with monoclonal gammopathy and polyneuropathy, we selected the six patients who underwent SCT and retrospectively examined the effects of SCT on the disease course of the associated polyneuropathy. In all patients except one, the indication for SCT was hemato-oncological (multiple myeloma in 4 patients and primary AL amyloidosis in 1). The remaining patient had an IgG monoclonal gammopathy of undetermined significance and a progressive and painful polyneuropathy for which she was treated with SCT. SCT led to improvement of motor scores and autonomic symptoms in one patient; three patients experienced improvement of neuropathic pain or sensory deficits but showed further progression of weakness. One patient showed no improvement at all. One patient died within 100 days after SCT. In conclusion, SCT as a treatment of refractory hematological malignancy may occasionally have a positive effect on the associated progressive polyneuropathy, although the benefits are very limited and the treatment-related mortality is high.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of stem cell transplantation for B-cell malignancies on disease course of associated polyneuropathy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…gefolgt von einem Ausschleichschema auf eine möglichst niedrige Erhaltungsdosis (▶Tab.). In schweren Fällen oder bei systemischer Beteiligung kann auch Cyclophosphamid gegeben werden (21) (26,27). Sehr limitiert sind die therapeutischen Optionen bei der multifokalen motorischen Neuropathie (MMN).…”

Section: Behandlung Der Immunneuropathienunclassified

Polyneuropathien

Doppler¹,

Sommer²

2015

Nervenheilkunde

View full text Add to dashboard Cite

ZusammenfassungPolyneuropathien können vielfältige Ursachen haben, die Abklärung erfordert daher eine systematische Diagnostik, wie sie in einschlägigen Leitlinien dargelegt ist. Wichtig ist die Detektion von kausal behandelbaren Neuropathien, dies sind meist die infektiösen und Immunneuropathien, jedoch auch die Amyloidneuropathien und einige der metabolisch verursachten Formen. In dieser Übersicht sollen die Diagnostik und Therapie der Polyneuropathien, mit Fokus auf den Immunneuropathien, zusammengefasst werden.

show abstract

S2e-Leitlinie: Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden

Sommer

2018

DGNeurologie

View full text Add to dashboard Cite

Auto-SCT in severe paraproteinemic neuropathy

Cited by 4 publications

References 10 publications

Effect of stem cell transplantation for B-cell malignancies on disease course of associated polyneuropathy

Effect of stem cell transplantation for B-cell malignancies on disease course of associated polyneuropathy

Polyneuropathien

S2e-Leitlinie: Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden

Contact Info

Product

Resources

About